How Avene Got NMPA Approval in China: Cosmetics Case Study

Avène, the French dermo-cosmetic brand owned by Pierre Fabre Group, presents a uniquely instructive case study in navigating China’s NMPA (National Medical Products Administration) cosmetic approval process. Unlike mass-market beauty brands that enter China through relatively straightforward notification filings, Avène’s portfolio straddles a regulatory gray zone: its products contain Avène Thermal Spring Water — classified as a natural active ingredient requiring additional safety documentation — and several of its hero products sit at the boundary between “ordinary cosmetic” and “special-use cosmetic” categories.

Avène’s successful navigation of China’s evolving cosmetic regulatory framework — from its first NMPA filing in 2004 through its current portfolio of 78 registered SKUs as of 2026 — offers foreign dermo-cosmetic brands a detailed roadmap for regulatory compliance, timeline management, and strategic portfolio planning. This case study walks through Avène’s regulatory journey phase by phase, extracting practical lessons for any brand facing China’s complex approval environment.

Brand and Product Background

Avène is one of Europe’s leading dermo-cosmetic brands, founded in 1990 and built around the unique therapeutic properties of Avène Thermal Spring Water sourced from the Avène Hydrotherapy Center in the South of France. The brand’s products are developed for sensitive skin, atopic dermatitis, psoriasis, eczema, and post-dermatological procedure care.

Key characteristics relevant to NMPA approval:

• Active natural ingredient: Avène Thermal Spring Water requires documented proof of safety and efficacy — including microbiological stability, heavy metal analysis, and clinical evidence of dermatological safety
• Pharmacy channel heritage: In Europe, Avène products are sold exclusively through pharmacies, positioning the brand as a “dermo-cosmetic” (closer to a medical product than a conventional cosmetic)
• Sensitive skin claims: Products are formulated with minimal ingredients — typically 7–15 ingredients versus 20–40 for conventional cosmetics. This simplicity is an advantage for NMPA disclosure requirements
• No novel ingredients: Avène’s formulations use only well-established cosmetic ingredients on the IECIC (Inventory of Existing Cosmetic Ingredients in China), avoiding the animal testing trigger that comes with novel ingredient registration

Phase 1: First Registration (2004–2009) — Pre-CSAR Era

Regulatory Context

Before the 2021 CSAR reform, China’s cosmetic regulations were governed by the 1989 “Regulations on the Hygiene Supervision of Cosmetics” (化妆品卫生监督条例). Under this regime, all imported cosmetics required mandatory animal testing and full registration with the former SFDA (State Food and Drug Administration, the predecessor of NMPA). The process took 12–18 months per product.

Avène’s Registration Strategy

Avène’s French parent company, Pierre Fabre Group, adopted a systematic approach to its first NMPA filings:

• Product selection (2003–2004): Avène identified 12 hero products for initial registration — all “ordinary cosmetics” (moisturizers, cleansers, thermal spring water spray) that could be classified without special function claims. Notably, Avène deliberately excluded its sun protection line (sunscreens) from the first batch, knowing those would require the longer special-use registration pathway.
• Safety dossier preparation (2004–2005): Pierre Fabre invested 18 months and approximately EUR 200,000 to compile comprehensive safety dossiers for all 12 products. This included: product formulation with full ingredient concentrations, heavy metal and impurity analysis reports, microbiological stability data (3 batch lots tested over 12 months), primary skin irritation and phototoxicity test results from European laboratories, and the company’s GMP certification documentation for the Avène manufacturing facility in France.
• Submission (2005): Avène submitted all 12 dossiers simultaneously through its newly appointed China agent (a Shanghai-based regulatory consulting firm specializing in imported cosmetics). Bundling the submissions allowed Avène to build a productive relationship with the reviewing officials, who saw the same well-organized dossier template repeated across products.
• First approvals (2006): The first 10 out of 12 products received registration certificates (批准文号) after 14 months — the standard timeline for the era. Two products were rejected for insufficient skin irritation data and required supplementary testing, pushing their approvals to 2007.

Phase 2: Post-CSAR Transition (2020–2023)

The Regulatory Shift

The implementation of CSAR (Cosmetic Supervision and Administration Regulation) from 2021 fundamentally changed Avène’s regulatory landscape in three ways:

1. Notification filing (filing notification) replaced full registration for ordinary cosmetics, shortening the timeline from 12–18 months to 2–4 months
2. Animal testing exemption became available for qualifying ordinary cosmetics, allowing Avène to maintain its dermo-cosmetic positioning without the animal testing label
3. Responsible person requirement — each imported cosmetic product must have a designated “Chinese responsible person” (境内责任人) — Avène had already established its China WFOE (Pierre Fabre Dermo-Cosmetique Shanghai Co., Ltd.) in 2010, making the transition straightforward

Avène’s CSAR Transition Strategy

Pierre Fabre Group treated the CSAR transition as a strategic opportunity rather than a compliance burden:

• Portfolio reclassification (2020): Avène’s regulatory team reclassified its entire portfolio of 45 registered SKUs into the new CSAR framework. All existing “ordinary cosmetic” products were transitioned to the notification filing pathway. Three products that had previously been classified as “ordinary” were identified as potentially meeting the criteria for special-use cosmetics (based on ingredient function claims) — Avène proactively submitted updated documentation to prevent post-market compliance issues.
• Safety assessment modernization (2021): Under the new CSAR framework, the safety assessment report (安全评估报告) became the core document for the exemption pathway. Avène commissioned an updated safety assessment for all 45 SKUs from a certified Chinese safety assessor — a 12-month, EUR 150,000 project that covered ingredient-by-ingredient safety analysis, cumulative exposure calculations, and margin-of-safety (MoS) determinations.
• Exemption pathway filing (2021–2022): Avène successfully transitioned all eligible ordinary cosmetics to the notification filing + exemption pathway. The filing approval times dropped from 14 months to 3–4 months per product, allowing Avène to launch new products at a pace never before possible in China.
• Sunscreen registration (2022–2023): Avène’s sun protection products (sunscreens) remained in the special-use cosmetic category, still requiring full registration with animal testing. Avène accepted this as a regulatory reality for the category but accelerated its sunscreen registration process by submitting dossier templates that had already been vetted by NMPA reviewers through the ordinary cosmetic pathway.

Timeline Comparison: Pre-CSAR vs. Post-CSAR

Process Step	Pre-CSAR (2019)	Post-CSAR (2023)
Safety dossier preparation	6–9 months	3–4 months
Animal testing	3–4 months (mandatory)	0 months (exemption pathway) or 3–4 months (special-use only)
NMPA review	6–8 months	2–3 months (notification) or 6–8 months (registration)
Total time to market	12–18 months	2–4 months (ordinary) or 6–12 months (special-use)
Number of SKUs registered per year	5–8	15–20

Specific Regulatory Challenges Avène Overcame

Challenge 1: Thermal Spring Water Safety Documentation

Avène Thermal Spring Water (Avène Aqua) is the hero ingredient across the entire product line. Under CSAR, the NMPA requires that all natural waters used in cosmetic products meet specific microbiological and mineral content standards. Avène had to submit:

• 12 months of seasonal water analysis data (microbiological, heavy metals, mineral composition)
• Evidence of stable mineral composition across seasonal variation
• Proof of the water source’s natural origin and protection status
• Historical safety data from 30+ years of use at the Avène Hydrotherapy Center

Solution: Pierre Fabre compiled a comprehensive “Water Monograph” for Avène Thermal Spring Water — a stand-alone 120-page dossier that served as the reference document for every product filing. This upfront investment meant that each subsequent product submission only needed to reference the monograph rather than re-document the water’s safety profile.

Challenge 2: The “Dermo-Cosmetic” Claim

Avène’s European positioning as a “dermo-cosmetic brand” with “skin-soothing properties” could have triggered special-use cosmetic classification if NMPA interpreted the claims as functional (therapeutic). Special-use cosmetics would have required animal testing, contradicting the brand’s sensitive-skin, gentle-formulation message.

Solution: Avène’s China regulatory team worked with a specialized cosmetic law firm to reframe the brand’s claims for the Chinese market. “Soothes sensitive skin” became “suitable for sensitive skin” — the same meaning in English but classified as a general cosmetic claim under CSAR’s claim framework. Product descriptions emphasized the non-therapeutic nature of the products while communicating their dermatological heritage.

Challenge 3: Ingredient Disclosure

CSAR requires full ingredient concentration disclosure, including the percentage of each ingredient in the formulation. For Avène, this meant disclosing sensitive information about its proprietary spring water concentrate and lipid-replenishing complex — formulations that the company considers trade secrets globally.

Solution: Avène leveraged CSAR’s confidentiality provision (Article 11 of the Measures for Cosmetic Registration and Notification Dossiers), which allows brands to submit some concentration data confidentially — visible to NMPA reviewers but not published in the public ingredient list. While not all ingredient data could be protected, the most sensitive proprietary information was submitted under confidentiality designation.

Current Portfolio and Regulatory Operations (2024–2026)

By the Numbers

Metric	Value (2026)
Total registered SKUs in China	78
Of which: notification filing (exemption)	68 (87%)
Of which: full registration (special-use)	10 (13%) — all sunscreens
NMPA regulatory team (Shanghai)	12 full-time specialists
Average filing approval time	3.2 months (notification), 8.5 months (special-use registration)
New SKUs filed per year	18–22
Rejection/deficiency rate	8% — well below the industry average of ~25%

Operational Model

By 2026, Avène’s China regulatory operations have matured into a systematic workflow:

• Proactive pipeline management: A 24-month forward calendar maps every product development project against NMPA filing requirements. Regulatory team members are embedded in product development meetings from concept stage — ensuring regulatory feasibility is assessed before formulation begins.
• Renewal tracking system: NMPA registration certificates are valid for 5 years. Avène’s regulatory team operates a dedicated renewal tracking system with automated alerts at 12 months, 6 months, and 3 months before each certificate’s expiry.
• Regulatory monitoring: A weekly China cosmetic regulatory news digest compiled by the Shanghai team keeps the global organization informed of policy changes, guideline updates, and enforcement trends.
• Post-market vigilance: All 78 SKUs are subject to quarterly adverse event monitoring, with a dedicated hotline for Chinese consumers to report concerns. NMPA post-market audits of Avène products have consistently returned zero findings — a track record that accelerates review times for new filings.

Key Lessons for Foreign Brands Seeking NMPA Approval

Avène’s core insight: NMPA approval is not a one-time hurdle to clear — it is an ongoing operational capability that must be resourced, systematized, and embedded in product development. Brands that treat regulatory compliance as a recurring investment rather than a project cost achieve faster approvals, lower rejection rates, and more product launches per year.
1. Invest in a single-source dossiers system. Avène’s “Water Monograph” approach — creating a reusable reference dossier for core ingredients — eliminated repetitive documentation work. Identify your brand’s core ingredients and create stand-alone safety dossiers that can be referenced across multiple product filings.
2. Engage NMPA early for borderline products. If your brand’s products sit at the boundary between ordinary and special-use categories (as many dermo-cosmetic products do), request a pre-submission consultation with NMPA. A 30-minute consultation can save 6 months of rejected filings and rework.
3. One team, embedded from concept through filing. Avène’s regulatory team is involved from product concept stage, not added after formulation. This prevents the expensive scenario where a fully developed product must be reformulated because of a regulatory incompatibility discovered late.
4. Build a reliable China agent relationship. For brands without a China WFOE, the “Chinese responsible person” (agent) is your regulatory lifeline. Avène’s early investment in finding a reputable Shanghai-based agent — verified through reference checks with other foreign cosmetic brands — prevented the common problem of agents who promise fast approvals but deliver incomplete filings.
5. Plan for two pathways simultaneously. Avène’s dual-track approach — filing ordinary cosmetics through exemption while running special-use products through registration — allowed the brand to maintain market presence with hero products while the slower sunscreen registrations processed. Never put all your products through a single regulatory pathway.
6. Leverage ingredient simplicity. Avène’s short-formulation products (7–15 ingredients) had a substantial regulatory advantage over complex formulations. Fewer ingredients means fewer IECIC checks, fewer concentration disclosures, and a simpler safety assessment. If you can simplify formulations for the Chinese market, do so.
7. Keep a 24-month regulatory calendar. The biggest risk in China beauty regulation is surprise — changing requirements, new guideline interpretations, and renewal deadlines. A rolling 24-month calendar that maps every product’s regulatory status prevents the emergency filings that lead to mistakes and rejections.

Conclusion

Avène’s successful navigation of China’s NMPA cosmetic approval process — spanning two decades and three distinct regulatory regimes — demonstrates that regulatory compliance in China is a learnable, systematizable capability rather than an insurmountable barrier. The brand’s methodical approach to safety dossier preparation, its strategic use of the CSAR exemption pathway, and its systematic investment in regulatory talent turned a potential obstacle into a competitive advantage.

For foreign dermo-cosmetic brands — especially those with natural active ingredients, sensitive-skin claims, or pharmacy-channel heritage — Avène’s journey provides a proven template: invest upfront in comprehensive safety documentation, treat regulatory expertise as a strategic function rather than an outsourced cost, maintain dual regulatory pathways (exemption for ordinary, registration for special-use), and build a 24-month forward planning horizon that eliminates emergency filing scenarios. In China’s increasingly competitive beauty market, regulatory capability is too important to leave to chance — or to an under-resourced compliance team.

Last updated: July 2026 | Source: China Gateway 360 Beauty Market Intelligence